Relmada Therapeutics Inc. (NASDAQ: RLMD) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT RELMADA THERAPEUTICS INC.

Relmada Therapeutics Inc. (NASDAQ: RLMD)
Listen to this Section


$6.80
+0.1450 ( +2.18% ) 1.8M

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Clinical Trial Pipeline Stages


Drug Name Stage
REL-1017DetailsMajor depressive disorder, Mental health Phase 3
Psilocybin (REL-P11)DetailsObesity, Metabolic disorder Phase 1
REL-P11DetailsObesity, Metabolic disorder Phase 1

Market Data


Open $6.80
Previous Close $6.65
Volume 1.8M
Market Cap $697.52M
Day Range $6.54 - $6.97
52 Week Range $0.52 - $8.00
Shares Outstanding 104.89M
Change % +2.18%
Net Change ▲ 0.1450
Insider Ownership 0.01%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2014
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: 1,119,246.00

Date Type Amount Purchased Purchaser
2025-11-06 Buy 272500.00 TRAVERSA SERGIO
2025-11-06 Buy 500000.00 Shenouda Maged
2025-11-06 Buy 90000.00 Kelly Paul Edward
2025-11-06 Buy 136000.00 Ence Chuck
2025-08-28 Buy 80545.00 TRAVERSA SERGIO
2025-08-28 Buy 80545.00 TRAVERSA SERGIO
2025-05-20 Buy 172314.00 TRAVERSA SERGIO
2025-05-20 Buy 228961.00 Ence Chuck
2025-05-20 Buy 50000.00 Shenouda Maged
2025-05-20 Buy 200000.00 Kelly Paul Edward

SEC Filings


Form Type Description Pages Date
8-k 8K-related 14 Sep 16, 2025
8-k 8K-related 51 Sep 10, 2025
8-k 8K-related 12 Sep 02, 2025
4 Insider transactions 1 Aug 28, 2025
10-q Quarterly Reports 58 Aug 07, 2025
8-k 8K-related 51 Aug 07, 2025
8-k 8K-related 12 Jul 23, 2025
8-k 8K-related 12 Jul 10, 2025
4 Insider transactions 1 Jun 30, 2025
4 Insider transactions 1 Jun 30, 2025

Latest News


× Before browsing our site, please accept our cookies policy